Improving Lives Through Innovation
MEDICAL DEVICES
OCULENZ FOR AMD
Q3 2025
Technology Development Contract Manufacturing
OCULENZ SDK & DIGILOUPES
Q4 2026
OR-BOT +
ORLENZ AR & LIGHTFIELD3D
MONITOR Q1 2028
SATELLITE COMMERCIAL AEROSPACE
Additional development for non-medical (ADNOC, etc.)
Patient #1
• Brigadier General Richard Freeman was used to flying fighter jets at Mach 2. He was also an inventor and entrepreneur.
• Gen. Freeman was diagnosed with Advanced Macular Degeneration and could no longer fly, drive, manage his business or see his grandchildren.
• Unable to accept his life without vision, he challenged his sons to find a way to fix this dreadful disease.
Founders
• Brothers Michael and Mitch Freeman Invented “streaming mobile video” in the 90s, which became foundation for IEEE 802.11(n) MIMO standards.
• The Freemans old their technology and IP to Samsung in the 2000s – which is still is used when we send videos, use Facetime, Zoom, and 4G
• 100+ combined patents in several scientific fields
• Founded Ocutrx to correct their father’s AMD and ended up finding the solution to many problems faced by AR companies.
Mitchael Freeman COO
FORTHCOMING PRODUCTS
1 DigiLoupes for Surgeons
3
2 OR-Bot Surgery Visualization Theatre for Surgeons
What’s the problem?
Advanced Macular Degeneration (AMD) is a central vision disease affecting 200 million worldwide –and growing exponentially.
“Not only am I losing everything for myself, but I am also becoming a burden to my family & friends.”
-Linda, AMD patient
The Solution:
•Lightest weight and tetherless
•Indoor & outdoor use
•Widest field-of-view
•Patented hardware and software
•SaaS allows communication with doctor
•Wifi and cellular connectivity
•Offers magnification, contrast adjustment, and streaming text. Restores user independence
•Relinquishes caretaker responsibility
Commercialization scheduled late 2025
Another Problem: Traditional Loupes used by surgeons
• Unergonomic: Traditional Loupes are unergonomic, and cause Surgeons to need neck and back surgery themselves, some being forced to retire early.
• Analog: Fixed magnification, no connectivity options; not digital
• Costly: Ranging in price from $1,500 to $10,000. Surgeons often have multiple pairs.
Traditional Optical Loupes for medical & non-medical applications
The Solution:
✓ Optimized Ergonomics
✓ Adjustable Magnification
✓ All Digital
Unique Features
Self Contained: Wireless, tetherless, and handsfree. Hot swap battery allows battery to be changed without disrupting surgery feed.
Cinematic View: 5K and 8K resolution. Widest Field-of-View. 3D stereoscopic imaging.
All Digital: 5G, Wi-Fi, and Bluetooth connectivity, allowing for telesurgery.
Adjustable Magnification: Up to 20x adjustable zoom for unprecedented visualization of surgery site.
Ergonomic. Downward-facing cameras allow the surgeon to look forward while the headset looks down.
Problems in the OR
• Poor Ergonomics • Space Constrains • Inferior Resolution
The Solution
OR-Bot
LightField3D Holographic
Microscope
Surgery System
with 2 unique viewing options.
Unique Features
Visualization Option: OcuLenz AR Headset 5K resolution 120 degrees field-of-view
Visualization Option:
Lightfield3D Holographic Monitors
one for the surgeon one for nurses, techs, students
LightField3D Holographic Microscope 240x magnification
Headset
Commercialization Timeline
Q1 & Q2 2025
Q3 2025 OcuLenz for AMD Launch in USA
OcuLenz Patient Tests & Final Development Q1 2026 DigiLoupes FDA Trials Q4 2026 DigiLoupes Launch in USA Q1 2027 OR-Bot FDA Trials Q4 2027 OR-Bot Launch in USA
Manufacturing Subsidiary
Manufacturing Division
Spectrum AMT is a 28-year-old microelectronics manufacturer; purchased by Ocutrx in 2023. Capabilities:
• High-Reliability Circuit Card Assembly
• Electronic Systems & Assemblies
• Wiring & Harnessing
• Conformal Coating
• Environmental Testing
• Satellite Bus builds Industries we serve:
• Spaceflight
• Aerospace
• DoD & NATO
• Medical Devices
• Enterprise & Industrial
Customers
Analog Devices, Inc.
Air Force Academy (USAF)
Air Force Research Laboratory
Aspen Microsystems
ATS Energy
Fluke Corporation Geneva Technologies, Inc.
Global Comms Exchange, Inc.
General Atomics
Honeybee Robotics, Ltd.
Avanti Circuits, Inc.
BAE Systems, Inc.
Ball Aerospace
Blue Canyon Technologies
Blue Origin Space
Blue Line Engineering
Boeing Corporation
Broadcom Limited
CACI International, Inc.
D-Orbit USA
Design Sciences, Inc.
Defense Logistics Agency
Dynetics Corporation
Department of Defense (UIS)
Iris Technology
In Track Radar Technologies, Inc.
iSpace Technologies US, Inc.
Jet Propulsion Labs (JPL) NASA
Kaman Space and Defense
Keysight Technologies
L3 Harris, Inc.
Linear Automation
Lockheed Martin Corp
MIT Lincoln Labs
NASA
NASA (Goddard Space Flight Center)
NATO
Northrop Grumman
Raytheon, Inc.
Rockwell Automation
Royal Australian Navy
Sandia National Laboratories
Sanmina-SCI Corporation
Scientific Applications & Research Associates, Inc. (SARA)
SECOTEC, Inc.
SemQuest, Inc.
Sierra Space Corporation
SAIC
US Space Development Agency
Teledyne FLIR
Trident Vantage Systems, LLC
ThermoFisher Scientific
United Launch Alliance, LLC
US Navy Crane IUADP
Welkin Sciences, LLC
Western Digital Technologies
And more
Traction
• 70+ employees
• Employee longevity (18 years+)
• Commitment to Quality Manufacturing Instructors:
• NASA-STD-8739.1 Level B Instructor
• IPC/WHAM-A-620 BS Instructor
• IPC/J-STD-001 GS Instructor
Satellite Expansion
• Potential for over 1,000 satellite assemblies.
• Each satellite produces $1M-$2.5M in revenue.
• Potential revenue increase of over $1B over next 5 years.
• 40+ Employees & Consultants
• 50+ Medical Advisory Board Members
• 5 PhD, +20 Masters Level employees
• IEEE Senior Fellows
• 1 SPIE Senior Fellow Offices:
• Laguna Beach, California, USA
• Tulsa, Oklahoma, USA
• Frankfurt, Germany
• Dubai, UAE
80% of Ocutrx investors are surgeons who need our solutions.
50+ surgeons on our medical advisory boards.
Strategic Partners in negotiation Partnerships in our pipeline
116
Issued patents. Pending Patents. In several different patent families.
2025 Patent Portfolio Valuation. $85-$100M
Financials
Previous & Future Funding
Equity Raised: $19M
Debt Acquired: $25M acquisition of Spectrum WE ARE HERE
Round C: $50M @ $3.00 per share
Use of Capital: $50M USD
G&A, Patents, Clinical trials, Marketing, Fees, Infrastructure Expansion, Etc. $18M
$7M UAE Expansion
$5M
Commercialization of Medical Devices
$20M Spectrum AMT: Satellite Expansion & CapEx
Pro Forma
Ocutrx & Spectrum
Expected Dividends
Assumes
Exit Potentials
SALE
Investment Opportunity
The Opportunity
$50M USD
ROUND C
16,666,667 SHARES 17% OF THE COMPANY PER SHARE $3.00
$100K MINIMUM INVESTMENT
One Investment; two companies.
Compelling investment profile with natural hedge:
• High-growth innovation company
• Established, revenue-generating manufacturing business.
Emerging technology company, developing medical devices for patients and surgeons.
28-year-old manufacturing facility of advanced electronics with multiyear contracts.
Additional Resources
Click to Learn More
OcuLenz Patient Trial
Video
MEDTILES DIGITAL OVERLAY
ORLenz features
MedTiles Video
Spectrum’s Capabilities
Video